SAREPTA THERAPEUTICS comunicato
| News

SAREPTA THERAPEUTICS HAS ANNOUNCED POSITIVE DATA FOR SRP-9003 GENE THERAPY TRIAL

June 8th, 2020 - Sarepta Therapeutics has announced positive data for the SRP-9003 gene therapy trial for the treatment of type 2E Limb girdle  muscular dystrophy. The release reports positive data at 3 months of high-dose treatment. Furthermore, in patients treated at low doses there are still improvements even after 9 months of treatment.

read more

 

Other press releases:

New data gives hope for Limb Girdle Muscular Dystrophy gene therapy - Patient Worthy

SRP-9003 gene therapy for LGMD2E shows benefits after 1 year - Muscular  dystrophy news today

©2020 GFBONLUS.IT - GRUPPO FAMILIARI BETA-SARCOGLICANOPATIE
+39 328 0075986 This email address is being protected from spambots. You need JavaScript enabled to view it.

Via Civasca 112 23018 Talamona - SO  Italia

Made by Betsoft